Binder Groesswang has advised microbiome technology R&D company Biome Diagnostics on its investment round with Uniqa Group company SanusX. Schoenherr reportedly advised the investors.
Austria-based Biome Diagnostics, founded in 2018, has, according to Binder Groesswang, "been developing innovative microbiome-based technologies that use machine learning and DNA sequencing to analyze microbial functions [...] The aim is to develop first-class microbiome diagnostics and therapies that can be used in routine care and thus revolutionize cancer prevention in the future."
SanusX is an exploratory start-up established by the Uniqa Group in 2020. In addition to its own research work, SanusX regularly invests in up-and-coming medical technology startups.
According to Binder Groesswang, "together, SanusX and Biome Diagnostics now want to continue to grow and create new synergies to help even more people with new, accessible healthcare solutions."
The Binder Groesswang team was led by Partner Christian Zwick and included Partners Christine Dietz and Michael Horak, Senior Associates Christoph Raab and Sabine Apfl-Trumpeter, and Associate Michael Mittermair.
Editor's Note: After this article was published, Schoenherr confirmed it had advised SanusX on the acquisition of a participation in Biome Diagnostics in a capital increase transaction. The Schoenherr team was led by Counsel Gregor Petric and included Partner Marco Thorbauer, Counsel Iliyana Sirakova, Attorneys at Law Alexander Pabst, Nina Zafoschnig, Karin Pusch, Johannes Frank, and Tobias Hayden, and Associates Christina Unterduenhofen, Gabor Kulcsar, and Nikolaus Stepan.